Today: February 19, 2017, 7:39 pm

Research Report on China Antidiabetic Drug Market, 2014-2018 - New Market Study Published

Recently published research from CRI, "Research Report on China Antidiabetic Drug Market, 2014-2018", is now available at Fast Market Research 2014-03-23 12:45:51
In 2013, the diabetes prevalence rate of grown-ups aged in 20 to 79 was 8.3% in the globe. The number of sufferers reached 382 million. 80% of the patients lives in low to medium income countries. Meanwhile, the number of sufferers in these countries in increasing. The number of global diabetes sufferers is expected to be 592 million by 2035. In the current sufferer group, about 175 million people (46%) are not diagnosed or treated. In 2013, the global IGT prevalence rate was 6.9% and the number of sufferers was 316 million. The number is expected to be 474 million by 2035.

Full Report Details at
- ..

In 2013, there were 5.1 million people died from diseases related to diabetes, accounting for 8.4% of the total death number in the globe. The expenditure on diabetes reached USD 548 billion in the world, accounting for 11% of global medical treatment expenditure. The expenditure on diabetes related medical treatment will be USD 627.3 billion by 2035. Diabetes is growing prevalent in China and other developing countries, which is a heavy burden to the society and economy.

In 2013, the revenue of global diabetes treatment market exceeded USD 40 billion. The CAGR is expected to be 5% or more in next few years.

As China's society is further aging and obesity caused by improved living level and unhealthy lifestyle is increasing, the prevention and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the third chronic disease threatening the health of Chinese people.

The number of diabetes sufferers of China ranks the first in the world. In 2013, the number exceeded 110 million. Meanwhile, there are more than 400 million people in the diabetes prophase so the number will increase high in the next 10 years. The under-control rate of grown-up diabetic sufferers accepting treatment is lower than 40% for lacking medical care.

There are many antidiabetic drug varieties on China market, of which oral hypoglycemic drugs and insulin dominate the market. While new antidiabetic drugs like DPP-4 inhibitor, GLP-1 agonist, SGLT-2 inhibitor, etc. become hotspots in the globe, the classic drugs like Acarbose, Metformin, etc. still occupy most market share in China.

As the prevalence rate is growing and the living level and medical care level are improved, the market size of antidiabetic drugs is enlarged in China. In 2013, the market size exceeded CNY 20 billion. The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical enterprises, they will find huge market opportunities in China.

Through this report, the readers can acquire the following information:

* instance status of diabetes
* Supply and demand of China antidiabetic drugs
* Market status of sub-varieties of antidiabetic drugs
* Competition status of China antidiabetic drug market
* Market opportunities of antidiabetic drugs in China

The Following Enterprises and People Are Recommended to Purchase This Report:

* Pharmaceutical enterprises
* Medicine trading enterprises
* Medical Institutions
* Investors/research institutes concerned about China pharmaceutical market

Partial Table of Contents:

Table of Contents
1. Overview on Diabetes
1.1 Types of Diabetes
1.1.1 Type I Diabetes
1.1.2 Type II Diabetes
1.1.3 Other Diabetes
1.2 Epidemic Analysis of Diabetes
1.2.1 Incidence Status of Diabetes Around the World
1.2.2 Incidence Status of Diabetes in China

2 Therapies on Diabetes and Antidiabetic Drugs, 2009-2013
2.1 Therapies on Diabetes
2.1.1 Lifestyle Intervention
2.1.2 Antihyperglycemic Medication
2.2 Classification of Drugs
2.2.1 Insulin Drugs
2.2.2 Non-insulin Drugs
2.3 Analysis on Global Antidiabetic Drug Market
2.3.1 Analysis on New Drug Release on Global Antidiabetic Drug Market
2.3.2 Analysis on Size and Trend of Global Antidiabetic Drug Market
2.3.3 Analysis on Competition Pattern of Global Antidiabetic Drug Market
2.3.4 Analysis on Key Varieties in Global Antidiabetic Drug Market

3 Major Antidiabetic Drugs Applied in Clinic in China, 2009-2013
3.1 Insulin Preparation
3.2 Acarbose
3.3 Metformin
3.4 Repaglinide
3.5 Glimepiride
3.6 Rosiglitazone
3.7 Gliclazide
3.8 Gliquidone
3.9 Nateglinide
3.10 Glipizide
3.11 Others

4 Analysis on China Antidiabetic Drug Market, 2009-2013
4.1 Development Environment
4.1.1 Policy Environment
4.1.2 Economic and Medical & Healthcare Environment
4.2 Market Size
4.3 Competition Pattern of China Hospital-use Antidiabetic Drug Market, 2009-2013
4.3.1 Competition Pattern of Drugs
4.3.2 Competition Pattern of Manufacturing Enterprises
4.3.3 Analysis on Drug Varieties in Completion

5 Major Manufacturing Enterprises (Totals 15-20) in China Antidiabetic Drug Market, 2009-2013
5.1 Foreign Funded Enterprises
5.1.1 Novo Nordisk (China) Pharmaceutical Co., Ltd.
5.1.2 Eli Lilly and Company
5.1.3 Sanofi-Aventis
5.1.4 Bayer
5.2 Chinese Domestic Enterprises

6 Prospect of Global and China Antidiabetic Drug Market, 2014-2018
6.1 Forecast on Market Size
6.1.1 Global Market Size
6.1.2 China Market Size
6.2 Status Quo and Trend of Global Antidiabetic Drug R&D
6.2.1 R&D Focuses of Antidiabetic Drugs
6.2.2 Analysis on New Antidiabetic Drugs in Research
6.3 Status Quo of China Antidiabetic Drug R&D
6.3.1 R&D Focuses of Antidiabetic Drugs
6.3.2 New Antidiabetic Drugs in Research

Full Table of Contents is available at:

About CRI

CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 930 Words
Related Articles
More From Health
Why are most women disappointed in bed [..]
In a recent study 384 women asked “What can make sex an unpleasant experience for you?”. 84.9% answered that the [..]
Active Clinics recently introduced cryotherapy treatments to The Midlands in UK to help individuals with various skin problems look [..]
DERMATOLOGIE- CANCER : Des doutes sur des grains [..]
DERMATOLOGIE- CANCER : Des doutes sur des grains de beauté ? Plus besoin d’une biopsie invasive ! Le Centre Médical Incorpore [..]
Studies Show Eating Healthy Fats Help Sleep, [..]
The link between what we eat and how we sleep is closely related, especially when it comes to consuming healthy [..]
Studies on the Best Laxative Foods - [..]
It can make a person feel so healthy and energetic to have smooth digestion and elimination, and it can feel [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.